Enhancements to protocol, informed by recent ALRN-6924 data, are designed to improve the opportunity to demonstrate protection against chemotherapy-induced...
BOSTON, July 08, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer...
Patients on ALRN-6924 were able to stay on treatment longer, completing more of the first 4 cycles of carboplatin/pemetrexed (93% of cycles on ALRN-6924...
Aileron is developing ALRN-6924 to protect patients with p53 mutated cancers against chemotherapy-induced bone marrow toxicities and other toxicitiesTrial...
BOSTON, May 13, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer...
Taxanes, such as paclitaxel and docetaxel, cause severe and often permanent chemotherapy-induced hair loss (alopecia)New non-clinical data demonstrate...
On track to report interim results from Phase 1b clinical trial of ALRN-6924 in patients with advanced p53-mutated non-small cell lung cancer (NSCLC) in...
Here is how Aileron Therapeutics, Inc. (ALRN) and Paragon 28, Inc. (FNA) have performed compared to their sector so far this year.
Here is how Aileron Therapeutics, Inc. (ALRN) and Becton Dickinson (BDX) have performed compared to their sector so far this year.
Several anticipated catalysts in 2022 aim to advance Aileron’s vision to bring chemoprotection against multiple toxicities to all patients with p53-mutated...
